Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to 0.83%.

  • Xeris Biopharma Holdings' EBITDA Margin rose 298100.0% to 0.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.88%, marking a year-over-year increase of 277900.0%. This contributed to the annual value of 27.0% for FY2024, which is 109800.0% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported EBITDA Margin of 0.83% as of Q3 2025, which was up 298100.0% from 2.69% recorded in Q2 2025.
  • Xeris Biopharma Holdings' EBITDA Margin's 5-year high stood at 0.83% during Q3 2025, with a 5-year trough of 309.06% in Q2 2021.
  • Its 5-year average for EBITDA Margin is 87.67%, with a median of 46.73% in 2024.
  • In the last 5 years, Xeris Biopharma Holdings' EBITDA Margin plummeted by -639300bps in 2021 and then soared by 2056400bps in 2022.
  • Over the past 5 years, Xeris Biopharma Holdings' EBITDA Margin (Quarter) stood at 237.04% in 2021, then soared by 84bps to 38.97% in 2022, then increased by 23bps to 30.11% in 2023, then surged by 72bps to 8.52% in 2024, then soared by 110bps to 0.83% in 2025.
  • Its EBITDA Margin was 0.83% in Q3 2025, compared to 2.69% in Q2 2025 and 15.34% in Q1 2025.